News & Analysis on Clinical Trial Services & Contract Research And Development
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
Optimapharm has acquired MKS Research as it plans to double its revenue and become the largest independent contract research organization (CRO) in the Central and Eastern Europe (CEE) and South East Europe (SEE) regions.
Charles River Laboratories has acquired KWS BioTest in a deal that will expand the company’s immunology contract research services and geographical footprint.
Eisai Co Ltd has completed construction of an oral solid dose form manufacturing facility in Suzhou, China.
Recent changes in legislation are likely to increase the presence of foreign CMOs in China, says newly formed fill/finish firm Wuxi Griffin Pharmaceutical.
Teva Pharmaceutical Industries has confirmed it will close 20 to 25 API and drug manufacturing plants over the next two years.